The expansion of Processa Pharmaceuticals' NGC-Cap program into a new treatment area, specifically advanced or metastatic breast cancer, is a significant development that can potentially open up new revenue streams and market opportunities for the company. This type of news is typically received positively by investors as it indicates growth and innovation, which can lead to increased investor confidence and a potential short-term rise in stock price.